AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2018
Jan 17, 2018
29864_dirs_2018-01-17_239a2de4-08a2-45d1-8f10-c1b3463adc7c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2018-01-16
Reporting Person: ALTSHULER DAVID (EVP, Global Research and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-16 | Common Stock | S | 23813 | $155.77 | Disposed | 82198 | Direct |
| 2018-01-16 | Common Stock | S | 11767 | $156.63 | Disposed | 70431 | Direct |
| 2018-01-16 | Common Stock | S | 6130 | $157.71 | Disposed | 64301 | Direct |
| 2018-01-16 | Common Stock | S | 10585 | $158.82 | Disposed | 53716 | Direct |
| 2018-01-16 | Common Stock | S | 3955 | $159.41 | Disposed | 49761 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $155.77 (range $155.19 to $156.17).
F3: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $156.63 (range $156.19 to $157.18).
F5: Open market sales reported on this line occurred at a weighted average price of $157.71 (range $157.20 to $158.19).
F6: Open market sales reported on this line occurred at a weighted average price of $158.82 (range $158.21 to $159.20).
F7: Open market sales reported on this line occurred at a weighted average price of $159.41 (range $159.21 to $159.65).